Navigation Links
ATS Medical Announces Second Quarter 2009 Earnings Release Date and Conference Call
Date:7/27/2009

MINNEAPOLIS, July 27 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that it will release financial results for the second quarter ended July 4, 2009, after the market close on Monday, August 3, 2009. The Company will host a conference call and webcast on Monday, August 3, 2009 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its second quarter results and current corporate developments. The dial-in number for the conference call is 866-700-7477 for domestic participants and 617-213-8840 for international participants, with a passcode of 94675879. A live webcast of the call can be accessed at www.atsmedical.com by clicking on the Investors icon.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international participants, using the passcode 99143264. The webcast will also be archived on the Company's website.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site ishttp://www.atsmedical.com.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Midbrook Utilizes Copper in Medical Environments
2. Research Scientist Reports On Time-Tested Solution To Current Medical Crisis
3. Giant Bud Banner Half the Size of Football Field Flies Sunday Protesting Hydroponics Industry Cartel Monopoly that's Harming California's Medical Marijuana Patients
4. Mayor Julian Jolly Reseueollo Dialysis Center Officially Opens Doors With Support From Bridge of Life - DaVita Medical Missions
5. VA Medical Imaging Reaches Record Level
6. UCI Medical Affiliates, Inc.s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges
7. Neusoft Medicals Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market
8. U.S. Senator Sherrod Brown to Lend Support at MedWorks Free Medical Clinic This Weekend
9. Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation
10. Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards
11. Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology: